Adamis Pharmaceuticals Corp Company Profile (NASDAQ:ADMP)

About Adamis Pharmaceuticals Corp (NASDAQ:ADMP)

Adamis Pharmaceuticals Corp logoAdamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $89.4 million
  • Outstanding Shares: 22,634,000
Average Prices:
  • 50 Day Moving Avg: $4.06
  • 200 Day Moving Avg: $3.49
  • 52 Week Range: $2.40 - $9.08
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.93
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $6.47 million
  • Price / Sales: 13.82
  • Book Value: $1.15 per share
  • Price / Book: 3.43
Profitability:
  • EBIDTA: ($22,380,000.00)
  • Return on Equity: -155.07%
  • Return on Assets: -98.68%
Debt:
  • Current Ratio: 1.22%
  • Quick Ratio: 1.10%
Misc:
  • Average Volume: 485,851 shs.
  • Beta: -0.44
  • Short Ratio: 6.53
 

Frequently Asked Questions for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)

What is Adamis Pharmaceuticals Corp's stock symbol?

Adamis Pharmaceuticals Corp trades on the NASDAQ under the ticker symbol "ADMP."

How were Adamis Pharmaceuticals Corp's earnings last quarter?

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) posted its quarterly earnings results on Monday, November, 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.07. The company earned $2.08 million during the quarter. View Adamis Pharmaceuticals Corp's Earnings History.

Where is Adamis Pharmaceuticals Corp's stock going? Where will Adamis Pharmaceuticals Corp's stock price be in 2017?

2 equities research analysts have issued 12-month price targets for Adamis Pharmaceuticals Corp's stock. Their forecasts range from $5.00 to $10.00. On average, they expect Adamis Pharmaceuticals Corp's stock price to reach $7.50 in the next year. View Analyst Ratings for Adamis Pharmaceuticals Corp.

What are analysts saying about Adamis Pharmaceuticals Corp stock?

Here are some recent quotes from research analysts about Adamis Pharmaceuticals Corp stock:

  • 1. Maxim Group analysts commented, "News reports are out that there maybe as many as 80,000 plus defective EpiPens (which are being recalled across multiple countries) as a result of a possible failure (failure to inject). We see such news as yet another reason for a viable competitive product to be available in the marketplace... Adamis' valuation is compelling, in our view. At a sub-$100M market capitalization and with what we believe should be the next version of an EpiPen-like product (PFS), plus a pipeline of respiratory products and compounding pharmacy revenues set to build, we see Adamis as poised for a breakout year in 2017." (3/23/2017)
  • 2. According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (3/21/2017)

Who are some of Adamis Pharmaceuticals Corp's key competitors?

Who owns Adamis Pharmaceuticals Corp stock?

Adamis Pharmaceuticals Corp's stock is owned by many different of retail and institutional investors. Top institutional shareholders include PERCEPTIVE ADVISORS LLC (5.57%), PERCEPTIVE ADVISORS LLC (5.01%), Vanguard Group Inc. (0.00%), Bard Associates Inc. (0.00%), Leisure Capital Management (0.00%) and Axiom International Investors LLC DE (0.00%). Company insiders that own Adamis Pharmaceuticals Corp stock include David J Marguglio and Robert B Rothermel. View Institutional Ownership Trends for Adamis Pharmaceuticals Corp.

Who sold Adamis Pharmaceuticals Corp stock? Who is selling Adamis Pharmaceuticals Corp stock?

Adamis Pharmaceuticals Corp's stock was sold by a variety of institutional investors in the last quarter, including Leisure Capital Management and Bard Associates Inc.. View Insider Buying and Selling for Adamis Pharmaceuticals Corp.

Who bought Adamis Pharmaceuticals Corp stock? Who is buying Adamis Pharmaceuticals Corp stock?

Adamis Pharmaceuticals Corp's stock was purchased by a variety of institutional investors in the last quarter, including Axiom International Investors LLC DE, Vanguard Group Inc., Geode Capital Management LLC, Sterling Global Strategies LLC and Morgan Stanley. View Insider Buying and Selling for Adamis Pharmaceuticals Corp.

How do I buy Adamis Pharmaceuticals Corp stock?

Shares of Adamis Pharmaceuticals Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Adamis Pharmaceuticals Corp stock cost?

One share of Adamis Pharmaceuticals Corp stock can currently be purchased for approximately $3.95.

Analyst Ratings

Consensus Ratings for Adamis Pharmaceuticals Corp (NASDAQ:ADMP) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.50 (89.87% upside)

Analysts' Ratings History for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/23/2017Maxim GroupReiterated RatingBuy$10.00HighView Rating Details
1/24/2017B. RileyReiterated RatingBuy$5.00N/AView Rating Details
5/29/2015MizuhoInitiated CoverageBuy$10.00N/AView Rating Details
(Data available from 5/22/2015 forward)

Earnings

Earnings History for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
Earnings by Quarter for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
Earnings History by Quarter for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2016Q3 2016($0.48)($0.41)$2.08 millionViewN/AView Earnings Details
8/15/2016Q2($0.37)$1.93 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
2017 EPS Consensus Estimate: ($0.69)
2018 EPS Consensus Estimate: ($0.46)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.16)($0.16)($0.16)
Q3 20171($0.16)($0.16)($0.16)
Q4 20171($0.16)($0.16)($0.16)
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.11)($0.11)($0.11)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 13.74%
Insider Trades by Quarter for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
Institutional Ownership by Quarter for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
Insider Trades by Quarter for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/2/2016David J MarguglioVPSell700$9.00$6,300.00View SEC Filing  
5/16/2016David J MarguglioSVPSell4,000$8.08$32,320.00View SEC Filing  
5/9/2016David J MarguglioSVPSell4,860$10.00$48,600.00View SEC Filing  
5/4/2016David J MarguglioSVPSell4,860$9.17$44,566.20View SEC Filing  
5/3/2016David J MarguglioSVPSell1,140$9.00$10,260.00View SEC Filing  
4/14/2016David J MarguglioSVPSell12,000$7.52$90,240.00View SEC Filing  
8/14/2015Robert B RothermelDirectorBuy7,000$3.33$23,310.00View SEC Filing  
4/20/2015David J MarguglioSVPSell200$5.00$1,000.00View SEC Filing  
4/14/2015David J MarguglioSVPSell2,200$5.01$11,022.00View SEC Filing  
3/4/2015David J MarguglioSVPSell11,800$7.09$83,662.00View SEC Filing  
3/2/2015David J MarguglioSVPSell7,000$6.45$45,150.00View SEC Filing  
2/13/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell12,076$6.41$77,407.16View SEC Filing  
2/12/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell38,000$6.40$243,200.00View SEC Filing  
2/3/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell30,000$6.75$202,500.00View SEC Filing  
1/5/2015David J MarguglioVPSell7,000$6.18$43,260.00View SEC Filing  
12/30/2014David J MarguglioSVPSell12,228$6.09$74,468.52View SEC Filing  
12/29/2014David J MarguglioVPSell772$6.00$4,632.00View SEC Filing  
12/12/2014David J MarguglioSVPSell4,000$5.18$20,720.00View SEC Filing  
9/2/2014William C DenbyDirectorBuy2,500$5.06$12,650.00View SEC Filing  
8/29/2014Robert B RothermelDirectorBuy5,500$4.03$22,165.00View SEC Filing  
6/2/2014David J MarguglioSVPSell4,000$5.56$22,240.00View SEC Filing  
8/14/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell7,015$0.57$3,998.55View SEC Filing  
8/7/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell40,000$0.56$22,400.00View SEC Filing  
8/2/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell67,960$0.57$38,737.20View SEC Filing  
7/30/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell10,328$0.56$5,783.68View SEC Filing  
7/26/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell95,000$0.56$53,200.00View SEC Filing  
7/23/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell141,224$0.57$80,497.68View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
Latest Headlines for Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
Source:
DateHeadline
finance.yahoo.com logoBetting on Adamis Pharmaceuticals and Ocular Therapeutix Ahead of FDA Decisions
finance.yahoo.com - May 8 at 11:24 AM
americanbankingnews.com logo Adamis Pharmaceuticals Corp (ADMP) Given $7.50 Consensus Price Target by Analysts
www.americanbankingnews.com - May 5 at 9:18 AM
americanbankingnews.com logoAdamis Pharmaceuticals Corp (ADMP) Given Media Sentiment Rating of -0.25
www.americanbankingnews.com - May 2 at 10:08 AM
americanbankingnews.com logoAdamis Pharmaceuticals Corp (ADMP) Given News Impact Rating of -0.12
www.americanbankingnews.com - April 29 at 9:00 AM
finance.yahoo.com logoAdamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
finance.yahoo.com - April 26 at 8:31 PM
americanbankingnews.com logoAdamis Pharmaceuticals Corp (ADMP) Given Media Impact Score of 0.29
www.americanbankingnews.com - April 26 at 12:50 PM
americanbankingnews.com logoAdamis Pharmaceuticals Corp (ADMP) Receiving Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 23 at 7:38 AM
streetinsider.com logoAdamis Pharmaceuticals (ADMP) Prices 4.3M Shares at $3.50 - StreetInsider.com
www.streetinsider.com - April 22 at 3:20 PM
streetinsider.com logoPre-Open Movers 04/21: (OCN) (VBLT) (PFPT) Higher; (XBIT) (ADMP) (EFII) (MAT) Lower (more...)
www.streetinsider.com - April 21 at 8:20 PM
nasdaq.com logoMid-Day Market Update: CAI International Gains On Strong Results; Adamis Pharmaceuticals Shares Slide - Nasdaq
www.nasdaq.com - April 21 at 3:19 PM
streetinsider.com logoAdamis Pharmaceuticals (ADMP) to Offer Common Stock - StreetInsider.com
www.streetinsider.com - April 21 at 3:19 PM
finance.yahoo.com logoAdamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - April 21 at 3:19 PM
finance.yahoo.com logoAdamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 20 at 8:29 PM
americanbankingnews.com logoZacks: Analysts Set $7.50 Target Price for Adamis Pharmaceuticals Corp (ADMP)
www.americanbankingnews.com - April 20 at 11:19 AM
americanbankingnews.com logoAdamis Pharmaceuticals Corp (ADMP) Receives Media Sentiment Rating of 0.31
www.americanbankingnews.com - April 20 at 10:41 AM
americanbankingnews.com logoAdamis Pharmaceuticals Corp (ADMP) Given News Impact Score of -0.39
www.americanbankingnews.com - April 17 at 10:09 AM
americanbankingnews.com logoFavorable News Coverage Extremely Likely to Impact Adamis Pharmaceuticals Corp (ADMP) Share Price
www.americanbankingnews.com - April 13 at 8:50 AM
americanbankingnews.com logoAdamis Pharmaceuticals Corp (ADMP) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 6 at 11:51 AM
americanbankingnews.com logoZacks: Adamis Pharmaceuticals Corp (ADMP) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 5 at 9:31 AM
biz.yahoo.com logoADAMIS PHARMACEUTICALS CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 30 at 8:46 PM
americanbankingnews.com logoMaxim Group Reiterates "Buy" Rating for Adamis Pharmaceuticals Corp (ADMP)
www.americanbankingnews.com - March 23 at 3:55 PM
americanbankingnews.com logoAdamis Pharmaceuticals Corp (ADMP) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 21 at 8:46 PM
americanbankingnews.com logo Adamis Pharmaceuticals Corp (ADMP) Given $7.50 Average Price Target by Analysts
www.americanbankingnews.com - March 21 at 11:52 AM
finance.yahoo.com logoAdamis (ADMP) Shows Strength: Stock Gains 6.7% in Session
finance.yahoo.com - March 8 at 3:22 PM
finance.yahoo.com logoAdamis Pharmaceuticals (ADMP) Shares March Higher, Can It Continue?
finance.yahoo.com - March 7 at 3:20 PM
nasdaq.com logoIs the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock? - Nasdaq
www.nasdaq.com - February 27 at 3:29 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?
finance.yahoo.com - February 27 at 3:29 PM
barrons.com logoWhy Adamis Tops Impax Syringe at CVS Health - Barron's - Barron's
www.barrons.com - January 23 at 8:24 PM
barrons.com logo[$$] Why Adamis Tops Impax Syringe at CVS Health
www.barrons.com - January 23 at 3:21 PM
rttnews.com logoADMP Waiting To See If 3rd Time Is Charm, FDA Nod For SGYP, Be All Ears For OTIC
www.rttnews.com - January 21 at 1:24 AM
us.rd.yahoo.com logo9:00 am Adamis Pharma announces that the FDA has accepted for review the Company's New Drug Application for its Epinephrine Pre-filled Syringe product candidate for the emergency treatment of anaphylaxis
us.rd.yahoo.com - January 21 at 1:24 AM
nasdaq.com logoADMP Waiting To See If 3rd Time Is Charm, FDA Nod For SGYP, Be All Ears For OTIC - Nasdaq
www.nasdaq.com - January 20 at 3:23 PM
streetinsider.com logoAdamis Pharmaceuticals (ADMP) FDA Accepts Epinephrine Pre-Filled Syringe NDA Resubmission - StreetInsider.com
www.streetinsider.com - January 19 at 3:34 PM
finance.yahoo.com logoAdamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA
finance.yahoo.com - January 19 at 3:34 PM
biz.yahoo.com logoADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
biz.yahoo.com - January 11 at 3:28 PM
seekingalpha.com logoAdamis Pharmaceuticals: Beneficiary Of Mylan's EpiPen Fiasco? - Seeking Alpha
seekingalpha.com - January 6 at 3:26 PM
biz.yahoo.com logoADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Other Events
biz.yahoo.com - December 23 at 8:51 PM
streetinsider.com logoAdamis Pharmaceuticals (ADMP) Re-Submits Epinephrine Pre-Filled Syringe NDA - StreetInsider.com
www.streetinsider.com - December 16 at 3:26 PM
finance.yahoo.com logo9:03 am Adamis Pharma announces the resubmission of the Co's NDA to the FDA for its Epinephrine Pre-filled Syringe product candidate for the emergency treatment of anaphylaxis
finance.yahoo.com - December 16 at 3:26 PM

Social

Adamis Pharmaceuticals Corp (ADMP) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by MarketBeat.com Staff